InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,706.50
(
-0.12%
)
US TECH 100
19,268.40
(
-0.34%
)
Dow Jones
42,111.61
(
0.21%
)
Brent Oil
74.16
(
-0.22%
)
Bitcoin
62,889.27
(
-0.10%
)
Post# of 48
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Steveg

Send PM Follow Ignore
Followers 2
Posts 440
Boards Moderated 0
Alias Born 02/25/2004

Steveg

Re: None

Monday, 04/17/2006 11:23:09 AM

Monday, April 17, 2006 11:23:09 AM

Post# of 48
The Company submitted its 10-KSB Annual Report to the SEC. It includes an excellent discussion of the company's treatment methodology and patents. Of particular interest is how targeting overproduction of IFN-gamma is earlier in the immune system cascade than treatments already on the market that target other cytokines. This indicates the possibility, with some demonstrated results, of improved efficacy.

The Annual Report can be seen at the SEC website (http://www.sec.gov), and the Pinksheets website(http://www.pinksheets.com). I assume it will be posted on the company's website (http://www.advancedbiotherapy.com).

Steve

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up